Abstract:Atherosclerosis is a disease that is characterized by accumulation of lipids, cells and minerals at damaged sites of the arterial wall. It results in the development of a plaque, hardening of the artery and eventually the formation of thrombi. This leads to a decreased blood flow at the site of the plaque. Heart attacks and strokes that result from the decreased blood flow or the release of thrombi are the main cause of mortality in the western world. Many techniques are available to restore the blood flow at the site of the atherosclerotic lesion. Percutaneous transluminal angioplasty (PTA) is used most frequently. It involves the introduction of a balloon catheter at the site of the plaque. The balloon is inflated and deflated. The inflation and deflation procedure is repeated until the plaque is deformed to such an extent that the diameter equals the original diameter of the artery. Although the blood flow is initially restored, restenosis takes place in 30 to 50% of the patients within three to six months after the treatment. An important step in the process that leads to restenosis is the migration and proliferation of smooth muscle cells. Therefore, medication that prevents migration and proliferation of smooth muscle cells could lead to a reduction in the incidence of restenosis. As smooth muscle cell migration and proliferation take place in the first 4 weeks after treatment, sustained drug delivery for at least 1 month is desirable. Whereas systemic administration of drugs appeared to be inefficient and is hampered by adverse side effects, local delivery of drugs seems to be a promising approach. However, drugs locally delivered as an aqueous solution had a short residence time in the arterial wall. Therefore, drug carriers were used to extend the residence time of the drug in the arterial wall. Due to their small size, nanoparticles seem to be suited as a drug carrier, and the use of biodegradable polymers for the preparation of the nanoparticles minimizes the long-term risk of adverse tissue reactions. Furthermore, the use of particles allows modification of the surface, thus enhancing the targeting of particles in the arterial wall. It was the aim of this study to prepare, characterize and surface-modify biodegradable nanoparticles that can be used for the delivery of anti-proliferative drugs to atherosclerotic vascular walls. Furthermore, the degradation behavior of nanoparticles, the release of two anti-proliferative drugs from the nanoparticles and the delivery of nanoparticles to arterial porcine carotid arteries were studied in vitro.

Advanced Drug-Delivery Systems: Mechanoresponsive Nanoplatforms Applicable in Atherosclerosis Management

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Nanomedicine in cardiology: Precision drug delivery for enhanced patient outcomes

Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis

Biomimetic nanoparticles targeting atherosclerosis for diagnosis and therapy

Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis

Recent Advances in Targeted Stimuli-Responsive Nano-Based Drug Delivery Systems Combating Atherosclerosis

Atherosclerosis Treatment with Stimuli‐Responsive Nanoagents: Recent Advances and Future Perspectives

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis

Advances in stimulus-responsive nanomedicine for treatment and diagnosis of atherosclerosis

Engineered bioresponsive nanotherapeutics: recent advances in the treatment of atherosclerosis and ischemic-related disease

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Recent advances in inhibiting atherosclerosis and restenosis: from pathogenic factors, therapeutic molecules to nano-delivery strategies

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

Biodegradable Nanoparticles for Local Drug Delivery

Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis

Multi‐Pathway Microenvironment Regulation for Atherosclerosis Therapy Based on Beta‐Cyclodextrin/L‐Arginine/Au Nanomotors with Dual‐Mode Propulsion